7th World Congress on Oncology and Cancer Research with the theme “ADVANCING INTERACTIONS IN CLINICAL ONCOLOGY ” takes place on July 27-28, 2022 | Webinar.
7th World Congress on Oncology and Cancer Research will presents a supreme view to get bound with leading Scientists, Academicians, Specialists & Medical professionals, and Young Researchers coming from all over the globe. It is also a vast platform to present and intended to the most significant approach and matters in the field of Cancer Research, Clinical Oncology and Radiology.
This Oncology Congress 2022 conference will be coordinated around the theme “Advancing Interactions in Clinical Oncology”. This conference is the best moment for those who have engaged their focus on the cancer research and want to contribute it with the rest of the world. Presentations, sharing information, meetings with current and potential scientists, discussions on innovative developments and research, receiving recognition at this event are the main motive of this conference.
Renowned speakers across the world are greeted to talk about their researches and facts and also discuss the latest updates and innovative techniques for the treatment and surgery involved in oncology are sign of this Oncology Congress 2022.
- Cancer Research Institute's (Professors, Associate
Professors, Professionals, Lecturers, Scientists and students, Postdoctoral
fellows and Trainees)
- Directors, Head of Department
- Diagnostic Laboratory Professionals
- Cancer Pharmaceutical
- Diagnostics companies
- Rehabilitation Specialists
- Cancer Associations
The Organizing Committee of Oncology Congress 2022 will be happy to invite all participants around the globe to attend the “7th World Congress on Oncology and Cancer Research” is scheduled on July 27-28, 2022 | Webinar. The conferences will be focused on unique theme of “Advancing Interactions in Clinical Oncology”.
Oncology Congress 2022 Conference invites candidates from all prominent universities, medical and diagnostic facilities to contribute and feature their research aspects on all facets of this swift expanding field. Oncology Congress 2022 brings the opportunity and cheerful platform to boost these steps and fulfill the greatest demand ever through observation and intellectual correlations through these promising events. Allied Academies endorsed research conferences all over the world to progress and speed up analysis for an exceptional future with advance scientific studies.
Conferences of Allied Academies have amusing features like International Symposiums, B2B conferences, trade fairs, forums and global workshops for progressing domestic networking and effective educational and business partnerships. The 'Young Scientists Awards' are proposed by allied to the world's young scientists and academics.
Track 1: Cancer Biology
Cancer defines an immense spectrum of diseases that all emerge from uncontrolled biological growth. Broadly divided into benign tumors (unable to metastasize) or malignant tumors (able to invade normal tissues), cancers are more defined and classified by their cell type, tissue, or organ of element. Cancer remains the number two causes of death in the U.S., second only to heart disease, and the Intramural Research Program (IRP) is pledged to advancing explorations, building expertise, and resources to address this global challenge. Our scientists are steadily learning more about the causes of cancer, and growing new and better ways to prevent, detect, and treat it.
Causes of Cancer:
Cancer is a genetic disorder. It is acquired by a number of changes (mutations) in the chromosome in our body that control the advancement of cell or determine the detection and repair of DNA damage. One or more genes are involved in cancer evolution. Cancer is the result of combined mutations to a person’s DNA. The mutations that can lead to cancer may be genetic or procured.
Track 2: Cancers Biomarkers
Malignant rise of biomarkers also known as cancer biomarkers (CB) are bimolecular made either by the tumor cells or by various cells of the body in light of the tumor, and CB could be tested as screening/early point instrument of disease, demonstrative, prognostic, or index for the general result of a patient. Besides, malignancy biomarkers may categorize subpopulations of patients who are well on the way to react to a given therapy. Biomarkers can be qualities, elements, accurate cells, particles, catalysts, or chemicals which can be identified in blood, pee, tissues, or other body liquid.
- Chromosomal Changes
- Genomic Instability
- Gene Silencing
- Genetic Mutations
- Cell Lung Cancer Adhesion Molecules
Track 3: Cancer & Therapeutics
Cancer Therapeutics objective is to address the challenges of tumor heterogeneity, cancer advancement, and drug protection by utilizing a growing number of technologies feasible to doctors in the cure of this disease. It has gone through an ideal shift away from classic cytotoxic drug and toward targeting proteins that are factors to the cancer phenotype. The diagnosis and development of HSP90 inhibitors has been desired by cancer therapies as a means of wanted or overcoming medication resistance. All anticancer drugs work by prohibiting cell growth or normal function, DNA synthesis, and RNA and protein metabolite defect or mutation.
- Protein–protein interactions
- Cancer stem cells
- personalized medicine
- Kinase inhibitors
Track 4: Cancer Diagnosis
Diagnostics plays an essential role throughout cancer cure. Before treatment, to accurately diagnose Tumors, stage the illness, and regulate an appropriate combination of cancer diagnosis. Diagnostics are used to trail the size of the tumor, evolution of the disease, and patient response to treatment, and revise your treatment accordingly. To verify the diagnosis of most cancers, a liquid Biopsy needs is to be done in which a tissue sample is removed from the tumor which results initially and examined under a microscope for detecting tumor cells. Endoscopy is done by implanting a flexible plastic tube with a minute camera into body cavities or organs. Cancer Screening tests are used to identify the possibility of tumor cells which is present before symptoms result. To detect cancer at its initial stage, various types of diagnostic tests are used to Screen at-risk individuals, Monitor treatment efficacy and illness progression or recurrence, Predict prognosis and control treatment, Monitor an asymptomatic population for the early detection of cancer and treatment therefore drops cancer fatality, analyze a primary cancer and recognize the cancer subtype after whole cancer treatment, to feature for any signs of metastasis or recurrence.
- Cancer Endoscopy
- Cancer Biopsy
- Positron Emission Tomography (PET)
- 3D Single Photon Emission Computed Tomography (SPECT)
Track 5: Clinical trials on Oncology
A drug's clinical trial and economical availability are distinct by time. Groundwork’s such as medical need programs and compassionate use programs are in place to assurance patients have access to experimental, not-yet-authorized, or commercial drugs that are assisted by clinical evidence of virtue and safety. Clinical trials are used to find, assess, and approve the safety and virtue of experimental therapies such as innovative medications, innovative surgical/radiation procedures, and novel therapy solutions or strategies. Clinical trials present cancer patients who have failed to react to prior medications with therapeutic options in addition to medical knowledge. Oncology clinical trials try to prevent, diagnose, and cure cancer as well as take care of patient symptoms.
- Treatment trials
- Prevention trials
- Supportive and palliative care trials
Track 6: Radiation Oncology
Radiation oncology is a therapeutic treatment that is a crucial part of a multidisciplinary path to cancer treatment. It uses high energy photons usually delivered through a linear accelerator. Therapeutic x-rays are not at all awful and invisible and are used to treat a number of various cancers. The linear accelerator is secured within a cancer center and a team of radiation oncologists, nurses, radiation therapists and medical physicists will tell you about radiation therapy as a treatment choice, assess you, plan and bear your treatment as well as help you with any reactions you experience.
- Granulomatosis with polyangiitis
Track 7: Surgical Oncology
Surgical Oncology (SO) is celestially peer tested diary distributing unique diagnosis of both clinical and translational, extensive analysis, mixed media articles, and meta-investigations that add to the advancement of information in careful oncology. Sometimes, SO issue abnormal publications and editorial as they classify with chosen papers. SO's articles forward a matter of flow innovation in oncology research just as those unsettling clinical preliminaries, precise procedure, strategies for inspection and patient assessment/results.
- Diagnosis of PPB
- Treatment of PPB
- Types of PPB
- Pleuropulmonary Blastoma (PPB)
Track 8: Neuro-Oncology
Neuro-Oncology is the research of mind and spinal string neoplasms, a large number of which are (at any rate in the end) extremely uncertain and critical. Among the deadly cerebrum diseases, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (profoundly anaplastic) astrocytoma are among the worst. In these cases, untreated tolerance as a rule adds up to a couple of months, and tolerance with flow radiation and chemotherapy therapies may increase that time from around a year to eighteen months, feasibly at least two, unforeseen upon the patient's condition, insusceptible size, therapies utilized, and the particular kind of dangerous mind neoplasm. Medical proceeding may now and again be healing, in any case, when in doubt, critical cerebrum tumors will in general recover and rise out of reduction adequately, particularly profoundly threatening cases. In such cases, the objective is to extract as a large part of the mass (tumor cells) and however much of the tumor edge as could wisely be expected without compromising important capacities or other significant rational capacities.
Track 9: Hematology-Oncology
Hematology- Oncology is the field of medicine identical to the study of diagnosis, cure and prevention of blood diseases and cancer. It includes such disorders as iron deficiency anemia, hemophilia, sickle cell disorder, the thalassemia, leukemia and lymphoma. The study of hematology organize clinical and laboratory medicine. Leukemia affects your white blood cells. These are major, infection-fighting element of your immune system, made in your bone marrow. The carcinogenic pattern affecting the lymphocytes is called as lymphoma. As part of Myeloma, the plasma is damaged by the tumor cells. Blood cancers can cause various symptoms. Some are collective across all blood cancers; others are more peculiar types of blood cancer. For example, lymphomas can be identified by swollen lymph nodes and one of the most common symptoms of myeloma is bone pain, especially in the back.
- Blood transfusion
- Acute and Chronic blood cancer
Track 10: Cancer Prevention & Research
Cancer prevention is explicit as active methods to lower the risk of cancer. Most of cancer cases are due to coincidental risk factors, and many, but not all, of these environmental causes are controllable lifestyle option. An individual risk of growing cancer can be typically reduced by healthy management. Cancer Prevention Research grasps preclinical, clinical and translational study, with special thought given to molecular disclosure and significance on building a translational link between the primary and clinical sciences.
- Early Detection Research
- Avoiding Risk Factors
- Chemo preventive Measures
- Changing Lifestyle Choices
- Preclinical & Clinical Research
Market Analysis Report
Cancer is most frequent cause of death which stands second position in the world. Keep in mind that cancer isn't one sickness–it includes quite 200 diseases. The most common types of cancer were 1.4 million deaths per annum from lungs, 740,000 deaths from stomach cancer, 700,000 deaths caused liver cancer,610,000 colorectal cancer and 460,000 deaths from breast cancer.
The conference provides the participants of universities and institutes with an outstanding opportunity to interact with world-class scientists and industry professionals in cancer (or) oncology. Kids and individuals in the middle-aged population are highly prone to cancers such as leukaemia (34%), brain tumours (23%), and lymphomas (12%). These are also the most regular types of cancer in people of moderate age. Breast cancer in women is second to the cause of death from cancer in women.
70 new oncology therapies have been developed over the past five years and are used for treating over 20 different types of tumors. The global market size for cancer biomarkers was projected to hit USD 10.3 billion in 2016 and is forecast at USD 33.7 billion by 2025, up from 14.3 % with CAGR. The rise in malignancy in combination with the emphasis on targeted therapies is a major contributor to the growth of the industry.
In2015 there have been $78,238.9 million for global drug cancer market. Current patent exhalation of the most carcinogenic medicines and therefore the growing effects on the antineoplastic market is motivated by an increasing prevalence of various sorts of cancer, an increase in demand for biological and targeted treatment. The global drug market or Oncology / Cancer is estimated to raise$111.9 billion by 2020 and to record 7.1% of CAGR during the 2014 to 2020forecast period.
The market will accelerate at a CAGR of 13.02%. The market is expected to grow by $ 734.18 mn through 2021-2025. Increased prevalence of cancer will drive market growth over the forecast period. India is the key region featured in this research report.
In 2018, the global Oncology Nutrition market size was million USD and it is expected to reach million USD by the end of 2025, with a CAGR of 8.37 % between 2019 and 2025.In 2012, insights are transmitted in approximately 14.1million cases and 8.2million deaths. Malignancies from the lungs, hearts, stomach and bowels cause the world's most well-known deaths, accounting for nearly 60% of cancer deaths. In 2014, lung, kidney, colorectal and liver disorders were the most common sites of malignancy among men. In 5 ladies, generally the chest, ovary and stomach tumor were analyzed.
The leading regional cancer diagnostics and testing marketplace for North America is established. In 2015, a part of the general market in cancer diagnostics increased to approximately 40.7 %, followed by Europe, with a share in the cancer market of about 29.1%.
The report shows that the global market for oncology and cancer drugs produced $97.40 billion in 2017 and that $176.50 billion can be expected to reach by 2025, up from CAGR by 7.6 % somewhere in the range of 2018 and2025.
In 2018, the world market for carcinogenesis has been valued at USD 136.254,35 million and by 2024; it is estimated at USD 220.701,26 million, an 8.37% CAGR. Increased patient assistance programmes (PAPs), increased government cancer awareness programs, increased worldwide incidence of cancer, as well as strong R&D initiatives from key players have been some of the key factors driving market growth.
With its well-organized science programme, which includes in particular information on the latest cancer research and developments in the field of cancer research, Cancer 2022 offers experts, scientists, students and business delegates the simplest platform, and provides basic explanations behind cancer for current trends within the diagnostics and treatment of cancer. This international event is focused on the development of new methods for cancer treatment and cancer diagnosis, such as blood cancer, lung cancer, and cervical cancer. It also this lecture will also discuss cancer research pharmacology that helps find the cancer gun.
Who to attend?
- Academic Scientists
- Oncology Institutes
- Research faculty
- Medical Colleges
- Cancer Diagnostics Associations and Societies
- Diagnostic laboratory professions
- Industry professionals
- Business Entrepreneurs
- Presidents and Vice Presidents
- Brand Manufacturers/ Marketers of Consumer Products
- Marketing, Advertising and Promotion Agency Executives.